Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Declines By 11.0%

Immix Biopharma, Inc. (NASDAQ:IMMX) saw a large decline in short interest in December. As of December 31st, there was short interest totalling 356,500 shares, a decline of 11.0% from the December 15th total of 400,500 shares. Approximately 2.2% of the shares of the stock are sold short. Based on an average daily volume of 165,700 shares, the short-interest ratio is currently 2.2 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Immix Biopharma in a research note on Monday, January 6th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Invst LLC acquired a new position in Immix Biopharma in the 2nd quarter valued at about $57,000. FNY Investment Advisers LLC acquired a new position in Immix Biopharma in the 4th quarter valued at about $63,000. Finally, Geode Capital Management LLC raised its stake in Immix Biopharma by 5.6% in the 3rd quarter. Geode Capital Management LLC now owns 150,082 shares of the company’s stock valued at $224,000 after purchasing an additional 7,954 shares during the last quarter. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Trading Down 1.0 %

Shares of NASDAQ:IMMX traded down $0.02 during midday trading on Friday, hitting $2.04. 121,030 shares of the stock were exchanged, compared to its average volume of 140,296. The stock has a market cap of $56.12 million, a P/E ratio of -2.40 and a beta of 0.27. Immix Biopharma has a twelve month low of $1.26 and a twelve month high of $5.73. The company has a 50 day moving average price of $2.07 and a 200-day moving average price of $1.95.

Immix Biopharma (NASDAQ:IMMX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.08). On average, equities research analysts expect that Immix Biopharma will post -0.74 earnings per share for the current year.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.